The pharmaceutical companies behind Ozempic, Wegovy and other weight-loss meds push to prevent compounding pharmacies from ...

Treatment with tirzepatide demonstrated a 38% decrease in the risk of heart failure outcomes (composite endpoint) compared with placebo. Detailed results were announced from the phase 3 SUMMIT trial ...

GLP-1 drugs like Ozempic are injectable medications—but a strange new market has emerged selling oral “compounded” versions ...

(HealthDay News) — For patients with obesity and prediabetes, 3 years of tirzepatide yields substantial and sustained weight reduction and a reduced risk for progression to type 2 diabetes, according ...

Findings from a 3-year analysis demonstrated that among patients treated with tirzepatide, 98.8% remained diabetes free.

On November 16, at the 100th American Heart Association (AHA) Scientific Sessions 2024 in Chicago, Illinois, US, results were ...

The trial met both primary endpoints, with tirzepatide showing a 38% decrease in heart failure outcomes compared to placebo.

As millions patients struggled to fill their prescriptions for the new weight loss drugs, many have turned to compounded copies.

For patients with obesity and prediabetes, three years of tirzepatide yields substantial and sustained weight reduction and a reduced risk for progression to type 2 diabetes, according to a study ...

The GLP-1 tirzepatide, the active ingredient in Eli Lilly's Mounjaro, was found to reduce the risk of heart failure by 46% among individuals with obesity, according to a study published Nov. 16 in The ...

At 3 years in SURMOUNT-1, more than 90% of people remained diabetes-free with tirzepatide and maintained their initial weight loss, but the benefits reverted after the drug was stopped. SAN ANTONIO – ...

In just 10 months, she reached her weight loss goal with the help of the injectable semaglutide medication, Tirzepatide. 'I probably have not weighed this much since I was prepubescent,' Bonnie ...